Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure

Abstract Aims Impairment of vascular function contributes to the progression of chronic heart failure (HF) by increasing the afterload. Treatment with selective sodium‐glucose cotransporter 2 (SGLT2) inhibitors improves the prognosis of HF, but the precise mechanisms remain unclear. The aim of this...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Julie Kolwelter, Agnes Bosch, Susanne Jung, Lena Stabel, Dennis Kannenkeril, Christian Ott, Peter Bramlage, Mario Schiffer, Stephan Achenbach, Roland E. Schmieder
Médium: Artigo
Jazyk:Inglês
Vydáno: Wiley 2021-12-01
Edice:ESC Heart Failure
Témata:
Chronic heart failure
Empagliflozin
SGLT2 inhibitor
Vascular function
Central haemodynamics
Blood pressure
On-line přístup:https://doi.org/10.1002/ehf2.13622
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky